| Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial. | |
| | |
MedLine Citation:
|
PMID: 20478383 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Quercetin in culture with target cells and pathogens exerts anti-pathogenic activities against a wide variety of viruses and bacteria. A few small-scale human quercetin supplementation studies have produced conflicting results regarding quercetin's effects on upper respiratory tract infection rates, and little is known regarding the appropriate human dose. The purpose of this randomized, double-blinded, placebo-controlled trial was to measure the influence of two quercetin doses (500 and 1000 mg/day) compared to placebo on upper respiratory tract infection (URTI) rates in a large community group (N=1002) of subjects varying widely in age (18-85 years). Subjects ingested supplements for 12 weeks and logged URTI symptoms on a daily basis using the Wisconsin Upper Respiratory Symptom Survey (WURSS). No significant group differences were measured for URTI outcomes for all subjects combined, or when analyzing separately by gender, body mass index, and age categories. Regression analysis revealed that the strongest interaction effect with group status was self-reported fitness level. A separate analysis of subjects 40 years of age and older rating themselves in the top half of the entire group for fitness level (N=325) showed lower URTI severity (36% reduction, P=0.020) and URTI total sick days (31% reduction, P=0.048) for the Q-1000 group compared to placebo. In summary, for all subjects combined, quercetin supplementation over 12 weeks had no significant influence on URTI rates or symptomatology compared to placebo. A reduction in URTI total sick days and severity was noted in middle aged and older subjects ingesting 1000 mg quercetin/day for 12 weeks who rated themselves as physically fit. |
| | |
Authors:
|
Serena A Heinz; Dru A Henson; Melanie D Austin; Fuxia Jin; David C Nieman |
Related Documents
:
|
2968383 - Prevalence of bipolar disorder in a psychogeriatric population. 19594373 - Functional results 1 year after laser vaporization of the prostate: the impact of age. 10191843 - Adult ontogeny of rat working memory of social interactions. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-05-15 |
Journal Detail:
|
Title: Pharmacological research : the official journal of the Italian Pharmacological Society Volume: 62 ISSN: 1096-1186 ISO Abbreviation: Pharmacol. Res. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-07-08 Completed Date: 2010-10-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8907422 Medline TA: Pharmacol Res Country: England |
Other Details:
|
Languages: eng Pagination: 237-42 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Biology, Appalachian State University, Boone, NC 28608, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Anti-Bacterial Agents / blood, therapeutic use* Female Humans Male Middle Aged Placebos / administration & dosage, therapeutic use Quercetin / blood, therapeutic use* Respiratory Tract Infections / drug therapy* Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/Placebos; 117-39-5/Quercetin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of Estrogen Receptors, PKC and Src in ERK2 and p38 MAPK signaling triggered by 17beta-estradiol...
Next Document: Transposon-based screens for cancer gene discovery in mouse models.